Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317775 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Daniel Serrano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmerit International-An OPEN Health Company, Bethesda, MD, United States of America. Hauptthemen laut MEDLINE: Cystic Fibrosis, Patient Reported Outcome Measures, Psychometrics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals.
Abstract (Originalsprache)
The Cystic Fibrosis (CF) Impact Questionnaire (CF-IQ) was qualitatively developed to assess the impact of CF in the context of treatment advancements and increased longevity. This study reports the CF-IQ validation. In this noninterventional validation study, people with CF completed the 40-item CF-IQ and validating patient-reported outcome measures (PROMs) via electronic diaries at enrollment (baseline) and at the 4-week follow-up. Validation consisted of modern methods and focus groups to finalize structural validity, and classical methods to assess internal consistency [1–3], test-retest reliability [4,5], concurrent validity [5], and known-groups validity [5] of the CF-IQ. At baseline, 214 adults completed the survey; 193 completed the follow-up survey. Unidimensional item response theory (IRT) models were separately fit to 5 prespecified domains (Control and Burden of CF Treatment Impacts, Physical Activity Impacts, Social Activity Impacts, Emotional Impacts, and Work/School Limitation Impacts). IRT local dependence (LD) statistics identified 17 redundant items. Two independent CF-patient focus groups (14 total patients) confirmed these findings, and the 17 items were dropped. Each domain defined on the final 23 items achieved the criterion of exact model fit as measured by the root mean squared error of approximation (RMSEA, values = 0), Internal consistency (Cronbach’s α) values ranged from 0.81 to 0.89, 4 of 5 domains achieved acceptable test-retest reliability, with intraclass correlation coefficient (ICC) values ≥ 0.7, acceptable concurrent validity was achieved for all domains, and known-groups validity was established. The novel CF-IQ is a psychometrically robust PROM capturing patient-centric impacts of CF in the context of the current standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.
- The Psychometrics Team, Sheridan, WY, United States of America.
- Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
- INSERM U1151, Université Paris Cité, Centre de Références Maladies Rares Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.
ORCID-Profile: Daniel Serrano, Nicolai D Ayasse
Förderung
- Vertex Pharmaceuticals
Zitieren
APA
Serrano, D., Uzumcu, A., Gerstein, M., Ayasse, N. D., Engstrom, E., Barnes, F. B., Iaconangelo, C., Thorat, T., McGarry, L. J., & Sermet-Gaudelus, I. (2025). Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0317775
Vancouver
Serrano D, Uzumcu A, Gerstein M, Ayasse ND, Engstrom E, Barnes FB, et al. Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis. PLOS ONE. 2025. doi:10.1371/journal.pone.0317775
BibTeX
@article{Serrano2025,
author = {Serrano, Daniel and Uzumcu, Alyssa and Gerstein, Maya and Ayasse, Nicolai D and Engstrom, Ella and Barnes, Frederick B and Iaconangelo, Charles and Thorat, Teja and McGarry, Lisa J and Sermet-Gaudelus, Isabelle},
title = {Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317775}
}
EUVIMED